Patients with PTEN-deficient prostate cancer showed improvement in progression-free survival on Truqap plus standard therapy compared to standard therapy alone.
The patient died from complications linked to a rare hyperinflammatory syndrome associated with exposure to high doses of the AAV therapy delivery vehicle.
As the popularity of drugs like Ozempic and Mounjaro soar, researchers, doctors, biotechs, and diagnostic firms see a role ...
Researchers worked with two labs to identify 16 consensus lower-risk pathogenic variants and are pushing for greater ...
In a first-of-its-kind trial, physicians will review neurofilament test results with patients and decide whether to continue ...
The firms will initially develop a tool to identify NSCLC patients with EGFR mutations who can benefit from targeted therapy.
Hollings researchers will develop AI-driven tools to better match cancer patients to marketed therapies and clinical trials.
Jazz Pharmaceuticals Nabs FDA Accelerated Approval for Ziihera in HER2-Positive Biliary Tract Cancer
NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Jazz Pharmaceuticals' Ziihera (zanidatamab) as a treatment for advanced HER2-positive biliary tract cancer.
NEW YORK – Neuron23 this week detailed the design of its global Phase II trial, dubbed NEULARK, in which it is investigating a precision treatment strategy in early Parkinson's disease. Within the ...
NEW YORK – Aptose Biosciences on Wednesday said it began testing its multi-kinase inhibitor tuspetinib with azacitidine and AbbVie and Genentech's Venclexta (venetoclax) in a Phase I/II trial as a ...
The firm is also studying PTG-007 in patients with early-stage type 1 diabetes, but is looking for a partner for the pivotal trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback